4 completed. 1 Early Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Encysive Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) Bosentan, Sitaxsentan, Placebo - Pulmonary Arterial Hypertension, Vasodilation | Early Phase 1 | Completed | University of Edinburgh | 10 | 2009-01-01 | 2015-07-21 |
| Sitaxsentan in Proteinuric Chronic Kidney Disease Sitaxsentan, Nifedipine, Placebo tablet - Chronic Kidney Disease, Proteinuria | Phase 2 | Completed | University of Edinburgh | 27 | 2007-07-14 | 2025-02-07 |
| Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Argatroban - Thrombocytopenia, Thrombosis | Phase 4 | Completed | Encysive Pharmaceuticals | 24 | 2003-09-01 | 2007-01-11 |
| Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension sitaxsentan sodium - Pulmonary Hypertension | Phase 3 | Completed | Encysive Pharmaceuticals | 240 | 2003-05-01 | 2007-11-09 |
Pulmonary Arterial Hypertension (2) · Aneurysm (1) · Connective Tissue Diseases (1) · Heart Defects, Congenital (1) · Hypertension, Pulmonary (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1) · Scleroderma, Diffuse (1) · Thrombocytopenia (1) · Thrombosis (1)
sitaxsentan (2) · Bosentan (1) · Endothelin-3 (1) · Nifedipine (1) · argatroban (1)
United Kingdom (2) · United States (2)
David Webb, MD DSc FRCP FRSE FMedSci (1) · Neeraj Dhaun, MBChB (1)